PCSK9 inhibitor attenuates cardiac fibrosis in reperfusion injury rat by suppressing inflammatory response and TGF-β1/Smad3 pathway
Biochemical Pharmacology · 2024
DOI: 10.1016/j.bcp.2024.116563 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemical Pharmacology, 2024. Verfasst von Qing Huang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, Anshun City People's Hospital, Anshun 561000, Guizhou, China. Hauptthemen laut MEDLINE: Smad3 Protein, Transforming Growth Factor beta1, Fibrosis, PCSK9 Inhibitors. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: Health Commission of Guizhou Province.
Abstract (Originalsprache)
Progressive cardiac fibrosis, a hallmark of heart failure, remains poorly understood regarding Proprotein convertase subtilisin/kexin type 9 (PCSK9) 's role. This study aims to elucidate PCSK9's involvement in cardiac fibrosis. After ischemia/reperfusion (I/R) injury surgery in rats, PCSK9 inhibitors were used to examine their effects on the transforming growth factor-β1 (TGF-β1)/small mother against decapentaplegic 3 (Smad3) pathway and inflammation. Elevated PCSK9, TGF-β1, and Smad3 levels were observed in cardiac tissues post-I/R injury, indicating fibrosis. PCSK9 inhibition reduced pro-fibrotic protein expression, protecting the heart and mitigating I/R-induced damage and fibrosis. Additionally, it ameliorated cardiac inflammation and reduced post-myocardial infarction (MI) size, improving cardiac function and slowing heart failure progression. PCSK9 inhibitors significantly attenuate myocardial fibrosis induced by I/R via the TGF-β1/Smad3 pathway.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiovascular Medicine, Anshun City People's Hospital, Anshun 561000, Guizhou, China.
- Department of Hematology, Anshun City People's Hospital, Anshun 561000, Guizhou, China.
- Anshun Maternal and Child Health Care Hospital, Anshun 561000, Guizhou, China.
- Department of Cardiovascular Medicine, Anshun City People's Hospital, Anshun 561000, Guizhou, China. Electronic address: 419263483@qq.com.
Förderung
- Health Commission of Guizhou Province
Zitieren
APA
Huang, Q., Zhou, Z., Xu, L., Zhan, P., & Huang, G. (2024). PCSK9 inhibitor attenuates cardiac fibrosis in reperfusion injury rat by suppressing inflammatory response and TGF-β1/Smad3 pathway. Biochemical Pharmacology. https://doi.org/10.1016/j.bcp.2024.116563
Vancouver
Huang Q, Zhou Z, Xu L, Zhan P, Huang G. PCSK9 inhibitor attenuates cardiac fibrosis in reperfusion injury rat by suppressing inflammatory response and TGF-β1/Smad3 pathway. Biochemical Pharmacology. 2024. doi:10.1016/j.bcp.2024.116563
BibTeX
@article{Huang2024,
author = {Huang, Qing and Zhou, Zhina and Xu, Lei and Zhan, Peng and Huang, Guangwei},
title = {PCSK9 inhibitor attenuates cardiac fibrosis in reperfusion injury rat by suppressing inflammatory response and TGF-β1/Smad3 pathway},
journal = {Biochemical Pharmacology},
year = {2024},
doi = {10.1016/j.bcp.2024.116563}
}
EUVIMED